Advanced search
Publication Cover
OncoImmunology Volume 5, 2016 - Issue 5
Submit an article Journal homepage
4,927
Views
82
CrossRef citations to date
0
Altmetric
Original Research

PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations

Andreas H. ScheelInstitute of Pathology, University Hospital Cologne, Cologne, GermanyCorrespondence[email protected] [email protected]
,
Sascha AnsénCenter for Integrated Oncology Köln Bonn, Cologne, Germany;Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, GermanyCorrespondence[email protected] [email protected]
,
Anne M. SchultheisInstitute of Pathology, University Hospital Cologne, Cologne, Germany
,
Matthias SchefflerCenter for Integrated Oncology Köln Bonn, Cologne, Germany;Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
,
Rieke N. FischerCenter for Integrated Oncology Köln Bonn, Cologne, Germany;Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
,
Sebastian MichelsCenter for Integrated Oncology Köln Bonn, Cologne, Germany;Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
,
Martin HellmichInstitute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany
,
Julie GeorgeDepartment of Translational Genomics, Medical Faculty, University of Cologne, Cologne, Germany
,
Thomas ZanderCenter for Integrated Oncology Köln Bonn, Cologne, Germany;Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
,
Michael BrockmannDepartment of Pathology, Hospital Merheim, Cologne, Germany
,
Erich StoelbenThoracic Surgery, Lungenklinik Merheim, Kliniken der Stadt Köln gGmbH, Cologne, Germany
,
Harry GroenUniversity of Groningen and University Medical Center, Department of Pulmonary Diseases, Groningen, Netherlands
,
Wim TimensDepartment of Pathology, University of Groningen and University Medical Center Groningen, Groningen, Netherlands
,
Sven PernerPathology Network of the University Hospital of Luebeck and Leibniz Research Center Borstel, Luebeck and Borstel, Germany
,
Michael von Bergwelt-BaildonCenter for Integrated Oncology Köln Bonn, Cologne, Germany;Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
,
Reinhard BüttnerInstitute of Pathology, University Hospital Cologne, Cologne, Germany
&
Jürgen WolfCenter for Integrated Oncology Köln Bonn, Cologne, Germany;Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany
 show all
Article: e1131379 | Received 21 Oct 2015, Accepted 07 Dec 2015, Published online: 11 May 2016

Citations (82)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Loïck Galland, Anne Laure Le Page, Julie Lecuelle, Frederic Bibeau, Youssef Oulkhouir, Valentin Derangère, Caroline Truntzer & François Ghiringhelli. (2021) Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1. OncoImmunology 10:1.
Read now
Luca Mazzarella, Alessandro Guida & Giuseppe Curigliano. (2018) Cetuximab for treating non-small cell lung cancer. Expert Opinion on Biological Therapy 18:4, pages 483-493.
Read now

Articles from other publishers (80)

Luisa Vera Muscatello, Francesca Gobbo, Giancarlo Avallone, Micaela Innao, Cinzia Benazzi, Giulia D’Annunzio, Donatella Romaniello, Massimo Orioles, Mattia Lauriola & Giuseppe Sarli. (2023) PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems. Veterinary Pathology.
Crossref
Wei‐Chin Chang, Yu Zhi Zhang & Andrew G Nicholson. (2023) Pulmonary invasive mucinous adenocarcinoma. Histopathology.
Crossref
Chiara Ursino, Cécile Mouric, Laurent Gros, Nathalie Bonnefoy & Julien Faget. (2023) Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness. Frontiers in Immunology 14.
Crossref
Arthi Sridhar, Pawan Kumar Singh & Kaushal Parikh. (2023) Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions. International Journal of Cancer Care and Delivery 3:1.
Crossref
Junyong Weng, Shanbao Li, Zhonglin Zhu, Qi Liu, Ruoxin Zhang, Yufei Yang & Xinxiang Li. (2022) Exploring immunotherapy in colorectal cancer. Journal of Hematology & Oncology 15:1.
Crossref
Ea Maria Tønning Tønnesen, Magnus Stougaard, Peter Meldgaard & Johanne Lade-Keller. (2022) Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy . Journal of Clinical Pathology, pages jcp-2022-208574.
Crossref
Yunxia Ma, Rumyana Marinkova, Miljana Nenkov, Lai Jin, Otmar Huber, Jürgen Sonnemann, Natália Peca, Nikolaus Gaßler & Yuan Chen. (2022) Tumor-Intrinsic PD-L1 Exerts an Oncogenic Function through the Activation of the Wnt/β-Catenin Pathway in Human Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 23:19, pages 11031.
Crossref
Chenyue Zhang, Kai Wang, Jiamao Lin & Haiyong Wang. (2022) Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor . Future Oncology 18:27, pages 3031-3041.
Crossref
Qianqian Guo, Liwei Liu, Zelong Chen, Yannan Fan, Yang Zhou, Ziqiao Yuan & Wenzhou Zhang. (2022) Current treatments for non-small cell lung cancer. Frontiers in Oncology 12.
Crossref
Denise Zou, Weicheng Ye, Lisa M. Hess, Naleen Raj Bhandari, Amine Ale-Ali, Jacinda Foster, Peter Quon & Mack Harris. (2022) Diagnostic Value and Cost-Effectiveness of Next-Generation Sequencing–Based Testing for Treatment of Patients with Advanced/Metastatic Non-Squamous Non–Small-Cell Lung Cancer in the United States. The Journal of Molecular Diagnostics 24:8, pages 901-914.
Crossref
Lidia Gatto, Enrico Franceschi, Alicia Tosoni, Vincenzo Di Nunno, Stefania Bartolini & Alba Ariela Brandes. (2022) Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?. Immunotherapy 14:10, pages 799-813.
Crossref
Guanghui Wang, Haotian Zheng, Xiaogang Zhao, Yadong Wang, Yukai Zeng & Jiajun Du. (2022) The Prognostic Model and Drug Sensitivity of LKB1-Mutant Lung Adenocarcinoma Based on Immune Landscape. Frontiers in Molecular Biosciences 9.
Crossref
Bui Tien Cong, Pham Cam Phuong, Pham-Van Thai, Vu-Le Thuong, Nguyen Quang Hung, Dong-Thi Hang, Hoang Anh Tuan, Doan Minh Khuy, Pham-Van Tuyen & Nguyen Minh Duc. (2022) Prognostic Significance of PD-L1 Expression and Standardized Uptake Values in the Primary Lesions of Stage IV Adenocarcinoma Lung Cancer. Frontiers in Medicine 9.
Crossref
Yue Li, Chong Li, Ya Jiang, Xue Han, Sisi Liu, Xiuxiu Xu, Wanxiangfu Tang, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Minyan Xing, Yixiang Zhang & Yuezhen Wang. (2022) Correlation of PD-L1 Expression with Clinicopathological and Genomic Features in Chinese Non-Small-Cell Lung Cancer. Journal of Oncology 2022, pages 1-10.
Crossref
Kensuke Kojima, Tetsuki Sakamoto, Takahiko Kasai, Shinji Atagi & Hyungeun Yoon. (2022) A quantitative evaluation of the histological type dependence of the programmed death-ligand 1 expression in non-small cell lung cancer including various adenocarcinoma subtypes: a cross-sectional study. Japanese Journal of Clinical Oncology 52:3, pages 281-285.
Crossref
Thierry Landre, Gregoire Justeau, Jean-Baptiste Assié, Kader Chouahnia, Claire Davoine, Chérifa Taleb, Christos Chouaïd & Boris Duchemann. (2021) Anti-PD-(L)1 for KRAS-mutant advanced non-small–cell lung cancers: a meta-analysis of randomized–controlled trials. Cancer Immunology, Immunotherapy 71:3, pages 719-726.
Crossref
Takashi Sato, Kiyoshi Takagi, Mitsunori Higuchi, Hiroko Abe, Michie Kojimahara, Miho Sagawa, Megumi Tanaki, Yasuhiro Miki, Takashi Suzuki & Hiroshi Hojo. (2022) Immunolocalization of CD80 and CD86 in Non-Small Cell Lung Carcinoma: CD80 as a Potent Prognostic Factor. ACTA HISTOCHEMICA ET CYTOCHEMICA 55:1, pages 25-35.
Crossref
Liping Zhu, Dafu Ye, Tianyu Lei, Jie Wu, Wei Wang & Bin Xu. (2022) Cancer mutation profiles predict ICIs efficacy in patients with non-small cell lung cancer. Expert Reviews in Molecular Medicine 24.
Crossref
Rui An, Feng Zhao, Liqian Wang, Jikang Shan & Xianjun Wang. (2021) Predictive effect of molecular and clinical characteristics for the OS and PFS efficacy of anti-PD-1/PD-L1 immunotherapy in patients with NSCLC: a meta-analysis and systematic review. BMJ Open 11:12, pages e047663.
Crossref
Qiang Wen, Zhe Yang, Honghai Dai, Alei Feng & Qiang Li. (2021) Radiomics Study for Predicting the Expression of PD-L1 and Tumor Mutation Burden in Non-Small Cell Lung Cancer Based on CT Images and Clinicopathological Features. Frontiers in Oncology 11.
Crossref
Yuan Li, Zuhua Chen, Weiping Tao, Nan Sun & Jie He. (2021) Tumor mutation score is more powerful than tumor mutation burden in predicting response to immunotherapy in non-small cell lung cancer. Cancer Immunology, Immunotherapy 70:8, pages 2367-2378.
Crossref
Ivy Riano, Shruti R. Patel, Stephen V. Liu & Narjust Duma. (2021) Evidence to Date: Evaluating Pembrolizumab in the Treatment of Extensive-Stage Small-Cell Lung Cancer. Clinics and Practice 11:3, pages 441-454.
Crossref
Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung & Dae Seog Heo. (2021) Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer. The Korean Journal of Internal Medicine 36:4, pages 975-984.
Crossref
David M. Briere, Shuai Li, Andrew Calinisan, Niranjan Sudhakar, Ruth Aranda, Lauren Hargis, David H. Peng, Jiehui Deng, Lars D. Engstrom, Jill Hallin, Sole Gatto, Julio Fernandez-Banet, Adam Pavlicek, Kwok-Kin Wong, James G. Christensen & Peter Olson. (2021) The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Molecular Cancer Therapeutics 20:6, pages 975-985.
Crossref
Yi-Chun Chao, Kang-Yun Lee, Sheng-Ming Wu, Deng-Yu Kuo, Pei-Wei Shueng & Cheng-Wei Lin. (2021) Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer. International Journal of Molecular Sciences 22:11, pages 5649.
Crossref
Kaitang Huang, Meiling Hu, Jiayun Chen, Jinfen Wei, Jingxin Qin, Shudai Lin & Hongli Du. (2021) Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer. International Journal of Molecular Sciences 22:10, pages 5158.
Crossref
Alfredo Addeo, Antonio Passaro, Umberto Malapelle, Giuseppe Luigi Banna, Vivek Subbiah & Alex Friedlaender. (2021) Immunotherapy in non-small cell lung cancer harbouring driver mutations. Cancer Treatment Reviews 96, pages 102179.
Crossref
Li‐Na Pan, Yun‐Fang Ma, Zhen Li, Jia‐An Hu & Zhi‐Hong Xu. (2021) KRAS G12V mutation upregulates PD‐L1 expression via TGF‐β/EMT signaling pathway in human non‐small‐cell lung cancer. Cell Biology International.
Crossref
Meichen Gu, Tiankai Xu & Pengyu Chang. (2021) KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas . Therapeutic Advances in Medical Oncology 13, pages 175883592110069.
Crossref
Ravi Salgia, Rebecca Pharaon, Isa Mambetsariev, Arin Nam & Martin Sattler. (2021) The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). Cell Reports Medicine 2:1, pages 100186.
Crossref
Hanxiao Chen & Jun Zhao. (2020) KRAS oncogene may be another target conquered in non‐small cell lung cancer ( NSCLC ) . Thoracic Cancer 11:12, pages 3425-3435.
Crossref
Yuh-Min Chen, James Chih-Hsin Yang, Wu-Chou Su, Inn-Wen Chong, Te-Chun Hsia, Meng-Chih Lin, Gee-Chen Chang, Chao-Hua Chiu, Chao-Chi Ho, Shang-Yin Wu, Jen-Yu Hung, Chin-Chou Wang, Tsung-Ying Yang & Chong-Jen Yu. (2020) Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan. Journal of the Formosan Medical Association 119:12, pages 1817-1826.
Crossref
Fadhlina Harahap, Hartono Tjahjadi & Kusmardi Kusmardi. (2020) The potential of programmed death ligand-1 expression in ovarian malignant germ cell tumors as a prognostic factor. Revista Romana de Medicina de Laborator 28:4, pages 393-403.
Crossref
Riccardo Soffietti, Manmeet Ahluwalia, Nancy Lin & Roberta Rudà. (2020) Management of brain metastases according to molecular subtypes. Nature Reviews Neurology 16:10, pages 557-574.
Crossref
Eleni A. Karatrasoglou, Ilenia Chatziandreou, Stratigoula Sakellariou, Konstantinos Stamopoulos, Nikolaos Kavantzas, Andreas C. Lazaris, Penelope Korkolopoulou & Angelica A. Saetta. (2020) Association between PD-L1 expression and driver gene mutations in non-small cell lung cancer patients: correlation with clinical data. Virchows Archiv 477:2, pages 207-217.
Crossref
Roshal R. Patel, Shakti H. Ramkissoon, Jeffrey Ross & Lauren Weintraub. (2020) Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors. Pediatric Blood & Cancer 67:7.
Crossref
Jordi Remon, Francesco Passiglia, Myung-Ju Ahn, Fabrice Barlesi, Patrick M. Forde, Edward B. Garon, Scott Gettinger, Sarah B. Goldberg, Roy S. Herbst, Leora Horn, Kaoru Kubota, Shun Lu, Laura Mezquita, Luis Paz-Ares, Sanjay Popat, Kurt A. Schalper, Ferdinandos Skoulidis, Martin Reck, Alex A. Adjei & Giorgio V. Scagliotti. (2020) Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations. Journal of Thoracic Oncology 15:6, pages 914-947.
Crossref
Jie Qian, Wei Nie, Jun Lu, Lele Zhang, Yanwei Zhang, Bo Zhang, Shuyuan Wang, Minjuan Hu, Jianlin Xu, Yuqing Lou, Yu Dong, Yanjie Niu, Bo Yan, Runbo Zhong, Wei Zhang, Tianqing Chu, Hua Zhong & Baohui Han. (2020) Racial differences in characteristics and prognoses between Asian and white patients with nonsmall cell lung cancer receiving atezolizumab: An ancillary analysis of the POPLAR and OAK studies. International Journal of Cancer 146:11, pages 3124-3133.
Crossref
Francesco Romano, Antonino Giulio Giannone, Sergio Siragusa, Rossana Porcasi & Ada Maria Florena. (2020) Immunoistochemical expression of PD-1 and PD-L1 in bone marrow biopsies of patients with acute myeloid leukemia. Hematology Reports 12:1.
Crossref
Daniel Lenouvel, Miguel Ángel González‐Moles, Asmae Talbaoui, Pablo Ramos‐García, Lucía González‐Ruiz, Isabel Ruiz‐Ávila & José Antonio Gil‐Montoya. (2019) An update of knowledge on PD‐L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives. Oral Diseases 26:3, pages 511-526.
Crossref
Caichen Li, Jun Liu, Zhanhong Xie, Feng Zhu, Bo Cheng, Hengrui Liang, Jianfu Li, Shan Xiong, Zisheng Chen, Zhichao Liu, Yi Zhao, Limin Ou, Ran Zhong, Wei Wang, Jun Huang, Jinyun Sun, Chunya Zhang, Landong Weng, Jianxing He, Wenhua Liang & Zhenkui Pan. (2020) PD-L1 expression with respect to driver mutations in non-small cell lung cancer in an Asian population: a large study of 1370 cases in China. Therapeutic Advances in Medical Oncology 12, pages 175883592096584.
Crossref
Yanhui Chen, Quanxing Liu, Zhiming Chen, Yating Wang, Wanning Yang, Ying Hu, Wenbo Han, Hui Zeng, Haitao Ma, Jigang Dai & Henghui Zhang. (2019) PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Akihito Tsunoda, Kei Morikawa, Takeo Inoue, Teruomi Miyazawa, Masahiro Hoshikawa, Masayuki Takagi & Masamichi Mineshita. (2019) A prospective observational study to assess PD-L1 expression in small biopsy samples for non-small-cell lung cancer. BMC Cancer 19:1.
Crossref
Jianfei Yao, Yuan Gong, Wei Zhao, Zhifeng Han, Shaohua Guo, Hongyi Liu, Xiumei Peng, Wenhua Xiao, Yuemin Li, Shiying Dang, Guifeng Liu, Lifeng Li, Tanxiao Huang, Shifu Chen & Lele Song. (2019) Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. Scientific Reports 9:1.
Crossref
Ferdinandos Skoulidis & John V. Heymach. (2019) Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nature Reviews Cancer 19:9, pages 495-509.
Crossref
Anna-Lena Volckmar, Jonas Leichsenring, Martina Kirchner, Petros Christopoulos, Olaf Neumann, Jan Budczies, Cristiano Manuel Morais de Oliveira, Eugen Rempel, Ivo Buchhalter, Regine Brandt, Michael Allgäuer, Suranand Babu Talla, Moritz von Winterfeld, Esther Herpel, Benjamin Goeppert, Amelie Lier, Hauke Winter, Tilman Brummer, Stefan Fröhling, Martin Faehling, Jürgen R. Fischer, Claus Peter Heußel, Felix Herth, Felix Lasitschka, Peter Schirmacher, Michael Thomas, Volker Endris, Roland Penzel & Albrecht Stenzinger. (2019) Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases. International Journal of Cancer 145:3, pages 649-661.
Crossref
Sacha I. Rothschild. (2019) KRAS and Immune Checkpoint Inhibitors—Serendipity Raising Expectations. Journal of Thoracic Oncology 14:6, pages 951-954.
Crossref
Roberta Castiglione, Christina Alidousty, Barbara Holz, Svenja Wagener, Till Baar, Carina Heydt, Elke Binot, Susann Zupp, Anna Kron, Jürgen Wolf, Sabine Merkelbach-Bruse, Hans Christian Reinhardt, Reinhard Buettner & Anne Maria Schultheis. (2019) Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogies. Modern Pathology 32:5, pages 627-638.
Crossref
Åsa Kristina Öjlert, Ann Rita Halvorsen, Daniel Nebdal, Marius Lund‐Iversen, Steinar Solberg, Odd Terje Brustugun, Ole Christian Lingjærde & Åslaug Helland. (2019) The immune microenvironment in non‐small cell lung cancer is predictive of prognosis after surgery. Molecular Oncology 13:5, pages 1166-1179.
Crossref
Linda Ye, Connull Leslie, Angela Jacques, Nima Mesbah Ardakani, Benhur Amanuel & Michael Millward. (2019) Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features. Modern Pathology 32:4, pages 524-531.
Crossref
B.C.M. Hermans, J.L. Derks, E. Thunnissen, R.J. van Suylen, M.A. den Bakker, H.J.M. Groen, E.F. Smit, R.A. Damhuis, E.C. van den Broek, C.M. Stallinga, G.M. Roemen, E.J.M. Speel & A.-M.C. Dingemans. (2019) Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer 130, pages 179-186.
Crossref
Matthias Scheffler, Michaela A. Ihle, Rebecca Hein, Sabine Merkelbach-Bruse, Andreas H. Scheel, Janna Siemanowski, Johannes Brägelmann, Anna Kron, Nima Abedpour, Frank Ueckeroth, Merle Schüller, Sophia Koleczko, Sebastian Michels, Jana Fassunke, Helen Pasternack, Carina Heydt, Monika Serke, Rieke Fischer, Wolfgang Schulte, Ulrich Gerigk, Lucia Nogova, Yon-Dschun Ko, Diana S.Y. Abdulla, Richard Riedel, Karl-Otto Kambartel, Joachim Lorenz, Imke Sauerland, Winfried Randerath, Britta Kaminsky, Lars Hagmeyer, Christian Grohé, Anna Eisert, Rieke Frank, Leonie Gogl, Carsten Schaepers, Alessandra Holzem, Martin Hellmich, Roman K. Thomas, Martin Peifer, Martin L. Sos, Reinhard Büttner & Jürgen Wolf. (2019) K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways. Journal of Thoracic Oncology 14:4, pages 606-616.
Crossref
Clelia Madeddu, Paraskevas Kotsonis, Fabrizio Lavra, Giacomo Chiappe, Luca Melis, Ester Mura, Mario Scartozzi & Antonio Macciò. (2019) Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. Oncotarget 10:21, pages 2012-2021.
Crossref
Fatemeh K. Dermani, Pouria Samadi, Golebagh Rahmani, Alisa K. Kohlan & Rezvan Najafi. (2018) PD‐1/PD‐L1 immune checkpoint: Potential target for cancer therapy. Journal of Cellular Physiology 234:2, pages 1313-1325.
Crossref
Tomoyuki Miyazawa, Hideki Marushima, Hisashi Saji, Koji Kojima, Masahiro Hoshikawa, Masayuki Takagi & Haruhiko Nakamura. (2019) PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes. Annals of Thoracic and Cardiovascular Surgery 25:1, pages 1-9.
Crossref
Andrés F. Cardona, Leonardo Rojas, Zyanya Lucia Zatarain-Barrón, Helano C. Freitas, Sara T. Granados, Omar Castillo, George Oblitas, Luis Corrales, Christian D. Castro, Alejandro Ruiz-Patiño, Claudio Martín, María Angelina Pérez, Lisde González, Luis Chirinos, Carlos Vargas, Hernán Carranza, Jorge Otero, July Rodriguez, Jenny Rodriguez, Pilar Archila, Mauricio Lema, José Acosta Madiedo, Niki Karachaliu, Beatriz Wills, Luis E. Pino, Vladimir de Lima, Rafael Rosell & Oscar Arrieta. (2018) EGFR exon 20 insertion in lung adenocarcinomas among Hispanics (geno1.2-CLICaP). Lung Cancer 125, pages 265-272.
Crossref
Ra�l Barrera-Rodr�guez. (2018) Importance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker? (Review). Biomedical Reports.
Crossref
Marina Chiara Garassino, Alain Jonathan Gelibter, Francesco Grossi, Rita Chiari, Hector Soto Parra, Stefano Cascinu, Francesco Cognetti, Daniele Turci, Livio Blasi, Carmelo Bengala, Enrico Mini, Editta Baldini, Silvia Quadrini, Giovanni Luca Ceresoli, Paola Antonelli, Enrico Vasile, Carmine Pinto, Gianpiero Fasola, Domenico Galetta, Marianna Macerelli, Diana Giannarelli, Giuseppe Lo Russo & Filippo de Marinis. (2018) Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never-Smokers and EGFR-Mutant Patients. Journal of Thoracic Oncology 13:8, pages 1146-1155.
Crossref
Lori A. Ramkissoon, Nicholas Britt, Alexander Guevara, Emily Whitt, Eric Severson, Pratheesh Sathyan, Laurie Gay, Julia Elvin, Jeffrey S. Ross, Charlotte Brown, Kimberly Stogner-Underwood, Ryan Mott, David Kram, Roy Strowd, Glenn J. Lesser & Shakti H. Ramkissoon. (2018) Precision Neuro-oncology: the Role of Genomic Testing in the Management of Adult and Pediatric Gliomas. Current Treatment Options in Oncology 19:8.
Crossref
Yosuke Miura & Noriaki Sunaga. (2018) Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. Cancers 10:8, pages 245.
Crossref
Rieke Frank, Matthias Scheffler, Sabine Merkelbach-Bruse, Michaela A. Ihle, Anna Kron, Michael Rauer, Frank Ueckeroth, Katharina König, Sebastian Michels, Rieke Fischer, Anna Eisert, Jana Fassunke, Carina Heydt, Monika Serke, Yon-Dschun Ko, Ulrich Gerigk, Thomas Geist, Britta Kaminsky, Lukas C. Heukamp, Mathieu Clement-Ziza, Reinhard Büttner & Jürgen Wolf. (2018) Clinical and Pathological Characteristics of KEAP1 - and NFE2L2 -Mutated Non–Small Cell Lung Carcinoma (NSCLC) . Clinical Cancer Research 24:13, pages 3087-3096.
Crossref
Yiwei Liu, Zhengwei Dong, Tao Jiang, Likun Hou, Fengying Wu, Guanghui Gao, Yayi He, Jing Zhao, Xuefei Li, Chao Zhao, Wei Zhang, Qinrui Tian, Yingying Pan, Yan Wang, Shuo Yang, Chunyan Wu, Shengxiang Ren, Caicun Zhou, Jun Zhang & Fred R. Hirsch. (2018) Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. Clinical Lung Cancer 19:4, pages e421-e430.
Crossref
Yufei Zhang, Libin Wu, Zhen Li, Weiyi Zhang, Feifei Luo, Yiwei Chu & Guosong Chen. (2018) Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages. Biomacromolecules 19:6, pages 2098-2108.
Crossref
Hyojin Kim, Hyun Jung Kwon, Soo Young Park, Youngmi Park, Eunhyang Park & Jin-Haeng Chung. (2018) Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. PLOS ONE 13:6, pages e0198634.
Crossref
Xiaoliang WuLin ZhuPatrick C. Ma. (2018) Next-Generation Novel Noninvasive Cancer Molecular Diagnostics Platforms Beyond Tissues. American Society of Clinical Oncology Educational Book:38, pages 964-977.
Crossref
Yizhan Guo & Alexander Sasha Krupnick. (2018) There and back again: An immunotherapy tale. The Journal of Thoracic and Cardiovascular Surgery 155:4, pages 1771-1774.
Crossref
Wijendra Senarathne, Semir Vranic, Joanne Xiu, Inga Rose, Peggy Gates & Zoran Gatalica. (2018) Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. Annals of Diagnostic Pathology 33, pages 62-68.
Crossref
Anthousa Kythreotou, Abdul Siddique, Francesco A Mauri, Mark Bower & David J Pinato. (2018) PD-L1. Journal of Clinical Pathology 71:3, pages 189-194.
Crossref
Bo Lan, Chengxi Ma, Chengyan Zhang, Shoujie Chai, Pingli Wang, Liren Ding & Kai Wang. (2018) Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis. Oncotarget 9:7, pages 7684-7699.
Crossref
Donghai Xiong, Jing Pan, Yuxin Yin, Hui Jiang, Eva Szabo, Ronald A. Lubet, Yian Wang & Ming You. (2017) Novel mutational landscapes and expression signatures of lung squamous cell carcinoma. Oncotarget 9:7, pages 7424-7441.
Crossref
Marzia Del Re, Eleonora Rofi, Giuliana Restante, Stefania Crucitta, Elena Arrigoni, Stefano Fogli, Massimo Di Maio, Iacopo Petrini & Romano Danesi. (2017) Implications of KRAS mutations in acquired resistance to treatment in NSCLC. Oncotarget 9:5, pages 6630-6643.
Crossref
Yu-Chuan Ou, Joseph A. Webb, Christine M. O'Brien, Isaac J. Pence, Eugene C. Lin, Eden P. Paul, Danielle Cole, Shih-Hao Ou, Maryse Lapierre-Landry, Rossane C. DeLapp, Ethan S. Lippmann, Anita Mahadevan-Jansen & Rizia Bardhan. (2018) Diagnosis of immunomarkers in vivo via multiplexed surface enhanced Raman spectroscopy with gold nanostars . Nanoscale 10:27, pages 13092-13105.
Crossref
Robin Veenstra, Marie Kostine, Anne-Marie Cleton-Jansen, Noel FCC de Miranda & Judith VMG Bovée. (2018) Immune checkpoint inhibitors in sarcomas: in quest of predictive biomarkers. Laboratory Investigation 98:1, pages 41-50.
Crossref
Keith M Kerr & Gavin M Laing. 2018. Precision Molecular Pathology of Lung Cancer. Precision Molecular Pathology of Lung Cancer 257 273 .
Adrienne Johnson, Eric Severson, Laurie Gay, Jo-Anne Vergilio, Julia Elvin, James Suh, Sugganth Daniel, Mandy Covert, Garrett M. Frampton, Sigmund Hsu, Glenn J. Lesser, Kimberly Stogner-Underwood, Ryan T. Mott, Sarah Z. Rush, Jennifer J. Stanke, Sonika Dahiya, James Sun, Prasanth Reddy, Zachary R. Chalmers, Rachel Erlich, Yakov Chudnovsky, David Fabrizio, Alexa B. Schrock, Siraj Ali, Vincent Miller, Philip J. Stephens, Jeffrey Ross, John R. Crawford & Shakti H. Ramkissoon. (2017) Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. The Oncologist 22:12, pages 1478-1490.
Crossref
J. Hammerbacher & A. Snyder. (2017) Informatics for cancer immunotherapy. Annals of Oncology 28, pages xii56-xii73.
Crossref
Paweł Krawczyk, Bożena Jarosz, Tomasz Kucharczyk, Anna Grenda, Katarzyna Reszka, Juliusz Pankowski, Kamila Wojas-Krawczyk, Marcin Nicoś, Justyna Szumiło, Tomasz Trojanowski & Janusz Milanowski. (2017) Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes . Oncotarget 8:38, pages 64283-64293.
Crossref
Minghui Zhang, Dalong Wang, Qi Sun, Haihong Pu, Yan Wang, Shu Zhao, Yan Wang & Qiangyuan Zhang. (2017) Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pulmonary squamous cell carcinoma. Oncotarget 8:31, pages 51630-51640.
Crossref
Paul Hofman, Marius Ilié, Sandra Lassalle, Elodie Long, Coraline Bence, Catherine Butori & Véronique Hofman. (2017) Immunohistochimie PD-1/PD-L1 en oncologie thoracique : où en sommes-nous ?. Annales de Pathologie 37:1, pages 39-45.
Crossref
Samira Shojaee & Patrick Nana-Sinkam. (2017) Recent advances in the management of non-small cell lung cancer. F1000Research 6, pages 2110.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.